Previously, we showed that the cell-permeable compound SBI-756 binds to eIF4G1 and disrupts formation of the mRNA cap-binding complex in melanoma cells and in fibroblasts.19 To assess the effect of SBI-756 on eIF4F formation in lymphoma cells, we used a proximity ligation assay (PLA) to quantitate the interaction of eIF4E and eIF4G1 in situ. Here, EIF4G1 is linked to lymphoma.